Besides, the treatment of chronic hepatitis B adult patients in the immune tolerant phase are controversial and most of current clinical guidelines still recommend that those patients with high HBV DNA levels (typically > 106 IU/mL), positive HBeAg, and ALT (<30 U/L) need to receive antiviral therapy [10]. This evidence concerns the gene GPT and chronic hepatitis B virus infection.